Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.31 |
| ▸ | GRB2 | P62993 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27978897 | 1.00 | DPP4 (0.36) | DPP4DPP7DPP8S1PR4S1PR1 | |
| SCHEMBL14737789 | 0.86 | — | — | |
| SCHEMBL14737975 | 0.78 | HDAC1 (0.30) | — | |
| SCHEMBL7335665 | 0.76 | CCR1 (0.31) | — | |
| SCHEMBL25387512 | 0.68 | HDAC1 (0.40) | — | |
| SCHEMBL17653831 | 0.67 | ALDH1A1 (0.38) | — | |
| SCHEMBL14738957 | 0.66 | MEN1 (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL16829055 | 0.65 | PKM (0.41) | DPP4DPP7 | |
| Trifluoroacetic Acid SCHEMBL21048455 | 0.65 | PKM (0.41) | DPP4DPP7 | |
| SCHEMBL28048195 | 0.65 | GABRA5 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | DPP4 1636/4885DPP7 1316/4885DPP8 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.